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Background: Type 2 Diabetes mellitus (T2DM) affects persons of all ages, while also placing heavy economic
burdens on national economies and healthcare systems. The study aims to investigate the determinants of direct
medical cost (DMC), out-of-pocket (OOP) proportion of the cost, and healthcare utilization associated with T2DM.
Methods: This cross-sectional study was conducted in four major cities in China. Eligible subjects were adult
outpatients who received treatment at one of 15 sampled secondary or tertiary hospitals and consecutively
enrolled between March 2007 and May 2007. Generalized estimating equations were used to determine impact
factors associated with DMC and healthcare utilization.
Results: Insurance schemes and receiving insulin therapy were significantly associated with a higher annual DMC
of T2DM. For each increase in number of complications, there was about 33% increase in annual DMC. Insurance
schemes were significantly associated with the proportions of DMC from pocket. A 7% significantly lower
proportion of DMC was paid and 23% more clinic visits (AOR = 1.232, P < 0.001) were made by patients admitted
at secondary hospitals than tertiary hospitals. The group with higher income (> 2000 CNY/month) paid 23% less
from their pocket, compared with the lower income group. The number of complications also significantly
increased the outpatient visits (AOR = 1.064, P < 0.001).
Conclusions: It implies that preventing complications through the use of more effective treatment regimens is
important in order to control the healthcare expenditures of the diseases. Healthcare reform needs to be focused
on the medical insurance system and redistribution of patients in hospitals of different levels.
Background
Type 2 Diabetes mellitus (T2DM) affects people at all
ages. Nearly, 200 million people (or over 5% of the glo-
bal adult population) have diabetes worldwide, and this
number will increase up to 333 million (or 6.3% of the
global adult population) by 2025 [1]. In the developing
world, the prevalence was highest in Europe and Central
Asia and lowest in Sub-Saharan Africa. In China, the
total number of diabetes patients is currently 92.4 mil-
lion [2,3] and expected to double by 2030 [4].
T2DM is also a heavy economic burden on national
economies and healthcare systems, especially in develop-
ing countries[4]. The direct healthcare costs of diabetes
range from 2.5 to 15.0 percent of annual healthcare
budgets, depending on local prevalence and sophistica-
tion of the treatments available[5]. In China, it is
expected that the economic burden associated with
T2DM will increase dramatically in the next few decades
with the sharp increase of the number of diabetic
patients. Previous studies suggested that healthcare
expenses in people with diabetes were more than two
times greater than that in those without [6,7]. Major
costs for the disease include medical expenditures for
blood glucose level control and additional medicine and
service for diabetes related chronic complications, which
may lead to excess costs and additional consumption of
healthcare services [8].
Several factors were reported to have impact on over-
all economic burden in diabetic patients. Studies showed
that level of Hemoglobin A1c (HbA1c) and insulin
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costs [9-12]. Some other studies suggested sharing of
health expenditure, an index of equity in healthcare
financing, was associated with medical costs, and
affected by clinical characteristics and demographic fac-
tors as well [13,14]. Unreasonable healthcare utilization,
i.e., occurrence of hospitalization and number of outpa-
tient visits, which was associated with the increased
healthcare costs of T2DM [13,15], was affected by insur-
ance schemes and income levels [16,17].
The burden of diabetes has been a big challenge on
clinical and public health. So far, only limited studies
have been reported to identify the impact factors of
medical costs and healthcare utilization in T2DM popu-
lation. Moreover, those studies rarely addressed the
issues in the setting of developing countries. An analysis
of the demographic, socioeconomic and clinical influen-
cing factors that affect medical cost, sharing of expendi-
ture and health utilizations will help better understand
the increasing medical cost of T2DM, especially in
developing countries. The purpose of our study is to
investigate the determinants of direct medical cost
(DMC), out-of-pocket proportion (OOP) of the cost,
and healthcare utilization associated with T2DM in a
population of T2DM outpatients by a cross-sectional
survey conducted in four Chinese cities in order to help
healthcare policy makers to control the high medical




This cross-sectional study was conducted in four major
cities - Shanghai, Beijing, Guangzhou and Chengdu -
located in eastern, northern, southern and western
China, respectively.
Study subjects
Eligible subjects were adult outpatients who received
treatment at one of 15 secondary or tertiary hospitals
and met WHO criteria for diagnosis of T2DM [18].
Patients consecutively enrolled from each hospital’so u t -
patient clinics during 2 months period (March 2007 to
May 2007).
Subjects recruitment and data collection
Study coordinators with background of clinical medicine
or preventive medicine were hired from each study site
and trained by the investigators. Written informed con-
sents were obtained from all patients before enrollment.
Patients were interviewed face-to-face in the hospitals at
admission using a survey designed by the School of Pub-
lic Health, Fudan University. The survey included ques-
tions for patients’ demographics, diabetes characteristics,
existing complications caused by T2DM, and treatment
history, as well as self-estimations of the cost of T2DM
and its complications. This study was approved by the
Ethics Committee of the School of Public Health at
Fudan University.
Outcomes
The primary outcome of the study was DMC, defined as
the total expenditures for treating T2DM and related
complications, including co-payment, diagnosis, treat-
ment, diagnostic testing, prescription drugs and medical
supplies. Secondary outcomes included OOP proportion
and outpatient visits in recent 6 months. OOP propor-
tion was measured as a nonreimbursable expense paid
by a patient. It was calculated by a total of itemized
DMC paid by the patients without reimbursement vs.
total DMC in the past year. Outpatient visits in recent 6
months were measured by counting the times of visiting
outpatient department because of T2DM or diabetes
related complications during the past six months before
the survey.
Measurement
Demographic and socioeconomc characteristics, includ-
ing marital status (e.g., “Currently, your marital status
is...?”), education level (e.g., “Your level of education
is...?”), employment (e.g., “Are you currently working?”),
and monthly income (e.g., “Over the past 12 months,
approximately how much was your personal income per
month?”) were examined to explore the factors for out-
comes. Clinical characteristics (e.g., “During the past 12
months, did you take insulin therapy?"; “During the past
12 months, have you had the below concurrent disease
(s) diagnosed by a doctor?"; “When had your first
T2DM diagnosis been made?”) was also included in the
analysis.
China’s healthy care institutions are divided into three
levels (or tiers) in urban areas - primary institutions
(community hospitals or health centres that provide
basic healthcare services for communities), secondary
institutions (regional hospitals that provide comprehen-
sive medical care, medical education, and medical
research for the regions), and tertiary institutions (cross-
regional, providing comprehensive and specialized medi-
cal care with a high level of medical education and
research functions) (Guo ZH 1990). The level of the
hospitals where a patient enrolled to the study was also
included in the analysis.
In addition, all subjects were asked to take a HbA1c
test free of charge upon enrollment to the study. A fin-
ger tip blood sample (50ul) was collected from each
patient and sent to an assigned center in each city for
HbA1c test within 7 days using a standardized method
with Bio-Rad Variant II. Re-test of HbA1c were
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jects, 2% were randomly sampled for providing two fin-
ger blood samples at the same time, one for testing
on-site, and the other for re-test. The intra-class correla-
tion coefficient for the quality control (two tests) was
0.76, showing a good accordancy.
Statistical analysis
All data were entered into a Chinese database (EpiData
version 3.1) and transferred into STATA 9.0 statistical
package (STATA Corp, College Station, TX, USA) for
statistical analyses. Odds Ratios (OR) and their 95% con-
fidence intervals (95% CI) were computed using the
parameters’ estimates of the generalized estimating
equation (GEE) models and used for the interpretation
of the results. A 2-sided p-value < .05 was considered
statistically significant.
In this study, DMC and OOP proportion were measured
as continuous variables that are uncensored, positive-
valued, and skewed, while outpatient visits represent the
number of independent events that occur during a fixed
period of time (Table 1). Therefore, we used GEE models
to determine impact factors associated with the direct
medical cost and OOP proportion, with a Gamma distri-
bution and log link function; a GEE model with Poisson
distribution and loglinear function was performed to
explore the factors affecting outpatient visits in recent 6
months. Considering the characteristics of each city, we
managed city as a cluster variable in the GEE models.
Results
General characteristics and mean annual DMC of the
study participants
A total of 1530 subjects identified as type 2 diabetes
patients were recruited in the study period. Among them,
1478 patients met the inclusion criteria and offered infor-
mation on cost in analysis, of whom 41.7% were male and
58.7% enrolled in tertiary hospitals. Of the patients
enrolled, 91.1% were taking medications and 32.9% were
receving insulin therapy. Univariate analysis shows,
patients receving insulin therapy, having one or more
complications, suffering a long disease course (> 5 years)
had a significantly higher annual DMC (Table 2). The
higher income group (> 2000 CNY/month) had a higher
coverage (88.0%) of urban employee insurance than the
lower income group (77.9%).
Multivariate analysis of factors associated with direct
medical cost
Table 3 showed the influencing factors associated with
annual DMC. After ajustment for clustering on city, those
who were covered by commercial insurance (P < 0.001, vs.
none of insurance) and received insulin therapy (P <
0.001, vs. without insulin therapy) were significantly asso-
ciated with a higher annual DMC of T2DM, with 28% and
58% increase respectively. A significantlhy higher annual
DMC was paid by male patients than female patients (P =
0.039). The employed outpatients paid 12% less (P =
0.047) annual DMC than unemployed subjects. Moreover,
for each increase in number of complications (P < 0.001),
there was a 33% increase in annual DMC.
Multivariate analysis of factors affecting OOP proportion
of direct medical cost
The AOR of factors asscociated with OOP proportion
from DMC and its 95% CI were listed in Table 4. After
adjustment for clustering on city, a 7% significantly
lower proportion of DMC was paid by patients admitted
at secondary hosptals than tertiary hospitals (P < 0.001).
A significantly 8% higher proportion of DMC was paid
by employed patients than unemployed patients. The
group with higher income (> 2000 CNY/month) paid
26% less from their pocket, compared with the group
with lower income. Moreover, for each increased year in
disease course, we observed about 1% decrease in the
OOP proportion out of DMC.
Multivariate analysis of factors associated with outpatient
visits in recent 6 months
The factors associated with times of outpatient visits
were given in Table 5. After adjustment for clustering on
city, outpatients admitted at secondary hospitals had 23%
more clinic visits (AOR = 1.232, P < 0.001) than those at
tertiary hospitals. The number of complications also sig-
nificantly increased the outpatient visits (AOR = 1.064,
P < 0.001). There was a 6% increase of hospital visits for
each number increase of complications in outpatients.
Discussion
This cross-sectional study provided quantitative analysis
of the changes in healthcare expenditure and healthcare
service utilization caused by the incremental changes of
T2DM related complications, medical insurance
Table 1 Distributions of the outcome variables
Variables Mean(SD) Median(Quartiles) Range Skewness
DMC (CNY) 7926(13785) 4564(1916-9000) 219000 7.40
OOP proportions 0.47(0.39) 0.31(0.11-1.00) 1.00 0.33
Outpatient visits in recent 6 months 7.42(7.24) 6.00(3.00-10.00) 72 2.77
DMC: Direct medical costs, OOP: out-of-pocket
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Variables Value Number (%) Mean annual DMC (SE) P value*
City Beijing 375 (24.6) 8413 (430) 0.142
Guangzhou 376 (24.7) 8716 (829)
Shanghai 373 (24.5) 8095 (457)
Chengdu 400 (26.2) 6562 (975)
Sex Male 616 (41.7) 8410 (562) 0.254
Female 862 (58.3) 7581 (465)
Lifestyle intervention Yes 854 (57.9) 7772 (446) 0.618
No 622 (42.1) 8135 (592)
Drug therapy Yes 1346 (91.1) 7593 (357) 0.003
‡
No 130 (8.9) 11359 (1687)
Insulin therapy Yes 485 (32.9) 11047 (707) < 0.001
‡
No 990 (67.1) 6389 (399)
Medical insurance Urban employee insurance 1261 (85.3) 8275 (394) 0.080
Commercial insurance 18 (1.2) 8061 (1678)
Cooperative Medical Scheme 23 (1.6) 2965 (749)
None 176 (11.9) 6167 (1128)
Individual monthly income (CNY) < = 2000 1009 (68.3) 7523 (436) 0.099
> 2000 469 (31.7) 8795 (629)
Education level < = 9 years 637 (43.1) 7805 (552) 0.758
< 9 years 840 (56.9) 8028 (472)
Employed Yes 241 (15.9) 6571 (686) 0.093
No 1234 (84.1) 8201 (408)
Admission hospital Secondary 196 (13.3) 9202 (669) 0.233
Tertiary 1282 (86.7) 7759 (400)
Complication(s) Yes 792 (52.0) 10320 (633) < 0.001
‡
No 732 (48.0) 5372 (276)
Disease course < = 5 years 580 (38.1) 6416 (528) < 0.001
‡
> 5 years 944 (61.9) 8869 (478)
Note: total number amounts may vary due to missing values; SE: Std. Err; *: P values were obtained from one-way ANOVA test.; ‡:P<0 . 0 1 .
Table 3 Factors associated with annual DMC estimated by GEE
Variable AOR SE Z P value 95% CI
Insurance (Reference: none)
Urban employee insurance or resident insurance 1.243 0.219 1.23 0.217 0.880 1.757
Commercial insurance* 1.277 0.053 5.86 < 0.001
‡ 1.177 1.386
Cooperative Medical Scheme 0.463 0.192 -1.85 0.064 0.205 1.046
Lifestyle intervention: yes/no 0.988 0.110 -0.11 0.915 0.795 1.229
Drug therapy: yes/no 1.029 0.046 0.64 0.524 0.942 1.124
Insulin therapy: yes/no 1.575 0.162 4.42 < 0.001
‡ 1.288 1.927
Hospital: secondary/tertiary 1.215 0.138 1.72 0.085 0.973 1.517
Gender: male/female 1.146 0.076 2.06 0.039
† 1.007 1.305
Employed/non-employed 0.880 0.057 -1.99 0.047
† 0.775 0.998
Individual income: higher/lower 0.964 0.080 -0.44 0.657 0.820 1.134
Age (years) 1.002 0.004 0.52 0.600 0.994 1.011
Disease course (years) 0.996 0.008 -0.47 0.637 0.982 1.011
Education 1.017 0.093 0.19 0.849 0.851 1.217
Complication number 1.325 0.084 4.42 < 0.001
‡ 1.169 1.501
HbA1c value 0.980 0.039 -0.51 0.612 0.906 1.060
Note: Estimated by gamma log link function, using generalized estimating equations; adjusted for clustering on city.
DMC: direct medical costs; AOR: Adjusted Odds ratio; 95% CI: 95% confidence interval of AOR; SE: Std. Err; OOP: out-of-pocket; †: P < 0.05; ‡: P < 0.01. *: When
patients simultaneously had commercial insurance and other plans, they were categorized into the other groups.
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hospitals. To our knowledge, there is no similar data are
available for the comparison in China as well as in other
developing countries. Although a number of cost-of-ill-
ness studies have indicated that T2DM related compli-
cations significantly increased the costs for patients
[16,19-22], there have been few epidemiological or clini-
cal studies to systematically address the influncing fac-
tors of health expenditure of T2DM, especially in
developing countries like China.
As expected, there was an association between compli-
cations and annual DMC. By using the GEE model, we
found that for each increase in number of complica-
tions, there was a 33% increase in annual DMC, which
quantitatively proved that the high prevalence of dia-
betic patients who currently live with complications
(52% of the outpatients) has significantly increased the
economic burden of the type 2 diabetes. Moreover, each
increase in the number of complications resulted in
extra 6% hospital visits, which may explain the 33%
Table 4 Factors affecting OOP of annual DMC estimated by GEE
Variable AOR SE Z P value 95% CI
Insurance (Reference: none)
Urban employee insurance or resident insurance 0.556 0.113 -2.89 0.004
‡ 0.374 0.828
Commercial insurance* 0.616 0.131 -2.28 0.023
† 0.406 0.935
Cooperative medical scheme 0.812 0.071 -2.38 0.017
† 0.684 0.964
Lifestyle intervention: yes/no 0.992 0.096 -0.08 0.937 0.821 1.199
Drug therapy: yes/no 0.966 0.119 -0.28 0.780 0.760 1.229
Insulin therapy: yes/no 0.994 0.039 -0.16 0.876 0.920 1.074
Hospital: secondary/tertiary 0.934 0.009 -7.26 < 0.001
‡ 0.917 0.951
Gender: male/female 0.950 0.041 -1.20 0.229 0.873 1.033
Employment: employed/unemployed 1.083 0.040 2.14 0.033
† 1.007 1.165
Individual income: higher/lower 0.735 0.099 -2.29 0.022
† 0.565 0.956
Age (years) 0.988 0.004 -3.36 0.001
‡ 0.981 0.995
Disease course (years) 0.991 0.004 -2.40 0.016
† 0.984 0.998
Education 0.967 0.028 -1.19 0.235 0.914 1.022
Complication number 1.026 0.019 1.39 0.166 0.989 1.064
HbA1c value 1.019 0.018 1.05 0.294 0.984 1.055
Note: Estimated by gamma log link function, using generalized estimating equations; adjusted for clustering on city.
AOR: Adjusted Odds ratio; 95% CI: 95% confidence interval of AOR; SE: Std. Err; OOP: out-of-pocket; †: P < 0.05; ‡: P < 0.01. *: When patients simultaneously had
commercial insurance and other plans, they were categorized into the other groups.
Table 5 Factors associated with the outpatient visits in recent 6 months estimated by GEE
Variable AOR SE Z P value 95% CI
Insurance
Urban employee insurance or resident insurance/none 1.182 0.197 1.01 0.314 0.853 1.639
Commercial insurance/none* 1.014 0.148 0.10 0.924 0.762 1.349
Cooperative Medical Scheme/none 0.996 0.293 -0.01 0.988 0.559 1.774
Lifestyle intervention: yes/no 1.076 0.075 1.06 0.290 0.939 1.234
Drug therapy: yes/no 0.961 0.074 -0.52 0.603 0.827 1.117
Insulin therapy: yes/no 1.136 0.135 1.07 0.285 0.899 1.434
Hospital: secondary/tertiary 1.232 0.036 7.10 < 0.001
‡ 1.163 1.306
Gender: male/female 0.971 0.049 -0.59 0.553 0.879 1.071
Employed/non-employed 0.926 0.076 -0.94 0.349 0.788 1.088
Individual income: higher/lower 1.170 0.172 1.07 0.285 0.877 1.562
Age (years) 1.005 0.004 1.26 0.209 0.997 1.012
Disease course (years) 0.995 0.002 -2.15 0.032
† 0.991 1.000
Complication number 1.064 0.012 5.43 < 0.001
‡ 1.040 1.087
HbA1c value 0.976 0.013 -1.84 0.065 0.951 1.002
Note: Estimated by Poisson loglinear function, using generalized estimating equation models; adjusted for clustering on city.
AOR: Adjusted Odds ratio; 95% CI: 95% confidence interval of AOR; SE: Std. Err; †: P < 0.05; ‡: P < 0.01. *: When patients simultaneously had commercial
insurance and other plans, they were categorized into the other groups.
Wang et al. BMC Health Services Research 2010, 10:244
http://www.biomedcentral.com/1472-6963/10/244
Page 5 of 8increase of DMC by complications. Therefore, these
results strongly indicate that the prevention and treat-
ment of diabetes-related complications could therefore
not only improve the life quality and survival of patients
but also substantially reduce costs.
Our study show that different insurance schemes were
significantly associated with increased annual DMC of
T2DM. Although not significant, those covered by
urban employee insurance or resident insurance plan
had a 24% increase in annual DMC than those without
insurance plan; commercial insurance covered patients
were found having a significantly higher annual DMC
(28% increase). The result implies that the insured
patients may overuse the service, as indicated by the
widely accepted conventional theory of health insurance
based on the concept of moral hazard [23], which is
characterized by incremental average cost.
The latest Chinese national health survey in 2003 also
revealed that about 73% of people in rural areas who
should have sought medical treatment chose not to do
so due to cost [24]. However, the results did not corre-
late the outpatient visit with insurance schemes, which
had been reported in other settings [25,26]. It implies
that the types of insurance plans might affect the aver-
age charges of medical cost per visit, other than fre-
quency of seeking healthcare services for T2DM under
the current Chinese Health Insurance System. In fact,
the patients covered by health insurance scheme(s) had
significantly reduced the proportions of medical cost
from pocket, with 19% to 44% decrease in comparison
to those uncovered.
C h i n ah a sau r b a nh e a l t hi n s u r a n c es y s t e mt h a tp r o -
vides virtually sound coverage for people employed in
urban state enterprises and relatively inexpensive cover-
age for their families. The situation for workers in the
rural areas or in urban employment outside the state
sector is far more varied. Currently, about 55% of Chi-
nese urban residents are insured through this urban
programs[27]. For those who were from rural areas and
thus did not hold legal permanent urban residency sta-
tus might benefit from the Rural Cooperative Medical
System. Under this plan, each rural participant pays
only 10-20 CNY per year and is then eligible to receive
partial coverage of medical expenses, which ranges up
to 65 percent of total medical expenses[28]. There were
few exceptions for the above two plans, e.g., for unem-
ployed urban residents, who may get insured with a
relatively lower reimbursement proportions through a
so-called residents insurance plan. When the above
plans are absent, patients have to rely on commercial
health insurance or individually pay all medical costs.
We found patients with higher income (> 2000 CNY/
m o n t h )h a d2 3 %l e s sp a y m e n tf r o mt h e i rp o c k e ti n
comparison to those with lower income. Under current
China’s healthcare system, patients have to pay for treat-
ment out of their own pockets with large differences in
quality and access among income groups [29]. Under
the current health insurance system in China, the higher
income patients are more likely to be covered by insur-
ance or have a better insurance coverage than those
with lower income. Our result regarding the OOP is
consistent with the known fact. It should be particularly
noted that the fact may lead to a potential vicious circle
- the poorer the patients are, the relative higher propo-
tion of OOP cost they incur. The result is more worthy
of note when it was shown that more than 35% of
urban households of China had difficulty to afford
healthcare cost, or were poverished by the health costs
[30]. The employed outpatients paid less DMC but had
to pay more from their pocket (OOP), in comparison to
unemployed subjects. It may be caused by a fact that
m a n yo ft h eu n e m p l o y e dp e o p l ew e r er e t i r e dr e s i d e n t s
with high prevalence of chronic diseases but subjected
to a lower level of OOP according to the urban insur-
ance plan[31].
In response to growing public concerns over widening
inequalities in health, the Chinese Government officially
launched another round of the national health system
reform plan in early 2009 with a target of 90% health
insurance coverage by the end of 2010 and universal
coverage of essential healthcare by 2020. [32] Assuming
that the reform would be successful, the control of the
costs from diabetes may be more likely to depend on
the re-distributions of patients in different levels of hos-
pitals or community health centers. In this study, the
outpatients admitted at secondary hospitals had 23%
more hospital visits, but had 7% less payment of DMC
than those seeking medical services at tertiary hospitals.
This result is consistent with a study indicating that 6%
(997/17148) of tertiary hospitals nationwide consumed
55% of total healthcare expenditure in China [33]. As
T2DM can be mostly managed in primary care, our
study suggested an urgent need of redistribution
patients from tertiary hospitals, charcterized by provid-
ing comprehensive and intensive medical services, to
facilities where basic healthcare services is easy to be
accessed with lower prices.
Furthermore, the association between insulin therapy
and higher healthcare costs, that has been reported in
other settings(18, 19), was also confirmed in our study.
However, we did not find the association between DMC
and HbA1c, which had also been reported in other stu-
dies [10,34]. The reason may be that cost savings were
only significant among a portion of patients who have
the highest baseline HbA1c levels (≥1 0 % )b u tn o ti n
patients who have moderate or low HbA1c levels.
The findings from this study may be subject to several
limitations. First, the subjects of this study were patients
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applicable to other groups of patients. The generalizabil-
ity of the results was also limited by the geographic and
demographic characteristics of the study population,
considering that only 4 cities were selected as the sites.
Second, the cost data of this study, especially for direct
non-medical costs and indirect costs, were partially
based on patient recall, which may introduce a recall
bias. The DMC data that was based primarily on medi-
cal history combined with billing information, however,
was more precise and accurate. Finally, it was difficult
to differentiate T2DM-related complications from coin-
cidental diseases, particularly among the elderly, and
possibly some patients were misdiagnosed and therefore
stratified incorrectly.
Conclusion
T2DM related DMC varied with disease characteristics
(e.g., the number of complications), whereas the OOP
proportion of DMC was largely associated with socioe-
conomic factors. Our study implied that preventing
complications through the use of more effective treat-
ment regimens is important in order to control the
healthcare costs of the diseases. With early detection
and treatment, it is likely that the serious health conse-
quences of diabetes can be prevented or delayed and
thus the costs can be reduced. To reduce the inequity in
healthcare expenditures and utilizations of T2DM in dif-
ferent groups, healthcare reform needs to be focused on
the reforms of medical insurance system and redistribu-
tion of patients in different levels of hospitals.
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